Tarlatamab Shows Promise in SCLC

被引:0
作者
不详
机构
关键词
D O I
10.1158/2159-8290.CD-NB2023-0081
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tarlatamab, an investigational bispecific T-cell engager molecule that targets the cell surface protein delta-like ligand 3, has shown promising activity in patients with small cell lung cancer whose disease had progressed after receiving another therapy. Questions remain over whether clinicians and patients would use the drug given its challenging administration.
引用
收藏
页码:2494 / 2494
页数:1
相关论文
empty
未找到相关数据